Basic Information
| LncRNA/CircRNA Name | ASlnc04080 |
| Synonyms | SNHG12, ASLNC04080, C1orf79, LINC00100, NCRNA00100, PNAS-123 |
| Region | GRCh38_1:28578538-28582983 |
| Ensemble | ENSG00000197989 |
| Refseq | NR_024127 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | endometrial cancer |
| ICD-0-3 | NA |
| Methods | Microarray, qPCR etc. |
| Sample | endometrial carcinoma tissues |
| Expression Pattern | up-regulated |
| Function Description | ASLNC04080 was the most significantly upregulated lncRNA in microarray data, highly expressed in 22 out of 24 endometrial carcinoma tissues and HEC-1-B cell line. Moreover, the ASLNC04080 lncRNA expression was correlated with 19 coding genes, and may contribute to endometrial carcinoma genesis and progression by co-regulating with coding gene. Expression inhibition of lncRNA ASLNC04080 in HEC-1-B cells caused repression of cell proliferation, increased cell apoptosis, and G1 phase arrest. |
| Pubmed ID | 25695231 |
| Year | 2015 |
| Title | Microarray expression profile of lncRNAs and the upregulated ASLNC04080 lncRNA in human endometrial carcinoma. |
External Links
| Links for ASlnc04080 | GenBank HGNC NONCODE |
| Links for endometrial cancer | OMIM COSMIC |